Study: NCT06139536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4706 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4706 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4706 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4706 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4706 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308 Injection
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.